Dr Reddy's launches Propofol Injectable Emulsion in US market

Propofol Injectable Emulsion is a therapeutic equivalent generic version of Diprivan (Propofol) Injectable Emulsion," the company said in a BSE filing.

New Delhi: Dr Reddy's Laboratories on Thursday announced the launch of Propofol Injectable Emulsion, used for induction of general anaesthesia and sedation in intensive care units, in the US market.

Propofol Injectable Emulsion is a therapeutic equivalent generic version of Diprivan (Propofol) Injectable Emulsion," the company said in a BSE filing.

Dr Reddy's said it uses distribution controls to market Propofol Injectable Emulsion, USP, to prevent any misuse.

Quoting IMS Health MAT data for twelve months ending in November 2018, Dr Reddy's Laboratories said Diprivan brand and generic had US sales of approximately $310 million.

Also Read: Dr Reddy’s gets four observations from USFDA for Andhra plant